CN101156848A - 卟啉类在制备声动力疗法药物中的应用及声动力疗法 - Google Patents
卟啉类在制备声动力疗法药物中的应用及声动力疗法 Download PDFInfo
- Publication number
- CN101156848A CN101156848A CNA2007101642443A CN200710164244A CN101156848A CN 101156848 A CN101156848 A CN 101156848A CN A2007101642443 A CNA2007101642443 A CN A2007101642443A CN 200710164244 A CN200710164244 A CN 200710164244A CN 101156848 A CN101156848 A CN 101156848A
- Authority
- CN
- China
- Prior art keywords
- aminoacid
- sound
- application
- tumor
- dynamic therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 60
- 239000003814 drug Substances 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims description 8
- 230000008450 motivation Effects 0.000 title description 5
- 150000004032 porphyrins Chemical class 0.000 title description 5
- -1 porphyrin chemical compound Chemical class 0.000 claims abstract description 22
- 235000001014 amino acid Nutrition 0.000 claims description 51
- 229940024606 amino acid Drugs 0.000 claims description 51
- 150000001413 amino acids Chemical class 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 38
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 35
- 239000004472 Lysine Substances 0.000 claims description 35
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 claims description 30
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 26
- 230000009471 action Effects 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 238000002604 ultrasonography Methods 0.000 claims description 8
- 229920001715 Porphyran Polymers 0.000 claims description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- ZNMSDGGOBMBEPZ-UHFFFAOYSA-N [ClH]1C=CCC1 Chemical compound [ClH]1C=CCC1 ZNMSDGGOBMBEPZ-UHFFFAOYSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 description 71
- 241000699670 Mus sp. Species 0.000 description 22
- 231100000489 sensitizer Toxicity 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- 238000011282 treatment Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 206010039491 Sarcoma Diseases 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000012449 Kunming mouse Methods 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229910052770 Uranium Inorganic materials 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910052771 Terbium Inorganic materials 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 229910052715 tantalum Inorganic materials 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010041303 Solar dermatitis Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- RKCAIXNGYQCCAL-UHFFFAOYSA-N porphin Chemical class N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 RKCAIXNGYQCCAL-UHFFFAOYSA-N 0.000 description 1
- CASUWPDYGGAUQV-UHFFFAOYSA-M potassium;methanol;hydroxide Chemical compound [OH-].[K+].OC CASUWPDYGGAUQV-UHFFFAOYSA-M 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000009214 sonodynamic therapy Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 150000003606 tin compounds Chemical class 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 平均肿瘤重量(g) | P(与C比较) | P(与U比较) | P(与E比较) |
C | 3.2200±0.1483 | <0.05 | <0.05 | |
U | 1.8400±0.3435 | <0.05 | >0.05 | |
E | 1.8800±0.3114 | <0.05 | >0.05 | |
EU3 | 0.5200±00.0837 | <0.01 | <0.01 | <0.01 |
组别 | 平均肿瘤重量(g) | P(与C比较) | P(与EU3比较) |
C | 3.2200±0.1483 | <0.01 | |
EU1 | 0.7600±0.0894 | <0.01 | <0.01 |
EU2 | 0.5800±0.0837 | <0.01 | >0.05 |
EU3 | 0.5200±0.0837 | <0.01 |
组别 | 平均肿瘤重量(g) | P(与C比较) |
C | 0.361±0.094 | |
U | 0.440±0.275 | >0.05 |
S | 0.272±0.328 | >0.05 |
SU3 | 0.009±0.003 | <0.01 |
组别 | 平均肿瘤重量(g) | P(与C比较) | P(与SU1比较) |
C | 0.361±0.094 | <0.05 | |
SU1 | 0.0425±0.025 | <0.05 | |
SU2 | 0.021±0.006 | <0.01 | <0.05 |
SU3 | 0.009±0.003 | <0.01 | <0.01 |
Claims (9)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101642443A CN101156848B (zh) | 2007-09-30 | 2007-09-30 | 卟啉类在制备声动力疗法药物中的应用 |
HK08110556.7A HK1121373A1 (en) | 2007-09-30 | 2008-09-23 | Use of porphyrin compounds in preparing a medicament for sonodynamic therapy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101642443A CN101156848B (zh) | 2007-09-30 | 2007-09-30 | 卟啉类在制备声动力疗法药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101156848A true CN101156848A (zh) | 2008-04-09 |
CN101156848B CN101156848B (zh) | 2011-01-19 |
Family
ID=39305173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101642443A Active CN101156848B (zh) | 2007-09-30 | 2007-09-30 | 卟啉类在制备声动力疗法药物中的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN101156848B (zh) |
HK (1) | HK1121373A1 (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009040411A1 (en) * | 2007-09-28 | 2009-04-02 | Photo Diagnostic Devices (Pdd) Limited | Photodynamic therapy and diagnosis using a chlorin e4 zinc complex |
CN102503947A (zh) * | 2011-11-02 | 2012-06-20 | 文剑 | 光氧动力治疗肿瘤用光敏剂二氢卟吩e6钛合物及制备方法 |
US8318794B2 (en) | 2008-11-25 | 2012-11-27 | Science Group Pty. Ltd. | Method of use of porphyrins in preparing a medicament for sonodynamic therapy and a method of sonodynamic therapy using porphyrins |
CN104277046A (zh) * | 2014-09-30 | 2015-01-14 | 海宁凤鸣叶绿素有限公司 | 叶绿素降解产物二氢卟吩e6衍生物的金属络合物及其制备方法和应用 |
CN104402894A (zh) * | 2014-09-30 | 2015-03-11 | 海宁市绿升医药科技有限公司 | 3-(1-烷氧乙基)二氢卟吩e6类似物的金属络合物及其制备方法和应用 |
CN105709275A (zh) * | 2014-12-02 | 2016-06-29 | 香港中文大学深圳研究院 | 超声响应性骨修复材料、制作方法及其用途 |
CN107987081A (zh) * | 2016-10-26 | 2018-05-04 | 刘辉 | 一种新型二氢卟吩e6衍生物及其药学上可接受的盐、其制备方法和应用 |
CN108030921A (zh) * | 2017-12-20 | 2018-05-15 | 深圳先进技术研究院 | 一种白蛋白负载金属卟啉配合物纳米颗粒的制备方法及其应用 |
CN108619096A (zh) * | 2017-03-21 | 2018-10-09 | 中国人民解放军军事医学科学院毒物药物研究所 | 声动力敏感脂质体、药物组合物及其用途 |
CN109568577A (zh) * | 2017-09-28 | 2019-04-05 | 中国科学院深圳先进技术研究院 | 一种用作光/声敏剂的靶向纳米颗粒及其制备方法和应用 |
-
2007
- 2007-09-30 CN CN2007101642443A patent/CN101156848B/zh active Active
-
2008
- 2008-09-23 HK HK08110556.7A patent/HK1121373A1/xx unknown
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009040411A1 (en) * | 2007-09-28 | 2009-04-02 | Photo Diagnostic Devices (Pdd) Limited | Photodynamic therapy and diagnosis using a chlorin e4 zinc complex |
US8318794B2 (en) | 2008-11-25 | 2012-11-27 | Science Group Pty. Ltd. | Method of use of porphyrins in preparing a medicament for sonodynamic therapy and a method of sonodynamic therapy using porphyrins |
CN102503947A (zh) * | 2011-11-02 | 2012-06-20 | 文剑 | 光氧动力治疗肿瘤用光敏剂二氢卟吩e6钛合物及制备方法 |
CN104277046A (zh) * | 2014-09-30 | 2015-01-14 | 海宁凤鸣叶绿素有限公司 | 叶绿素降解产物二氢卟吩e6衍生物的金属络合物及其制备方法和应用 |
CN104402894A (zh) * | 2014-09-30 | 2015-03-11 | 海宁市绿升医药科技有限公司 | 3-(1-烷氧乙基)二氢卟吩e6类似物的金属络合物及其制备方法和应用 |
CN104277046B (zh) * | 2014-09-30 | 2016-06-29 | 海宁凤鸣叶绿素有限公司 | 叶绿素降解产物二氢卟吩e6衍生物的金属络合物及其制备方法和应用 |
CN105709275A (zh) * | 2014-12-02 | 2016-06-29 | 香港中文大学深圳研究院 | 超声响应性骨修复材料、制作方法及其用途 |
CN107987081A (zh) * | 2016-10-26 | 2018-05-04 | 刘辉 | 一种新型二氢卟吩e6衍生物及其药学上可接受的盐、其制备方法和应用 |
CN107987081B (zh) * | 2016-10-26 | 2019-12-06 | 刘辉 | 一种二氢卟吩e6衍生物及其药学上可接受的盐、其制备方法和应用 |
CN108619096A (zh) * | 2017-03-21 | 2018-10-09 | 中国人民解放军军事医学科学院毒物药物研究所 | 声动力敏感脂质体、药物组合物及其用途 |
CN109568577A (zh) * | 2017-09-28 | 2019-04-05 | 中国科学院深圳先进技术研究院 | 一种用作光/声敏剂的靶向纳米颗粒及其制备方法和应用 |
CN109568577B (zh) * | 2017-09-28 | 2021-09-07 | 中国科学院深圳先进技术研究院 | 一种用作光/声敏剂的靶向纳米颗粒及其制备方法和应用 |
CN108030921A (zh) * | 2017-12-20 | 2018-05-15 | 深圳先进技术研究院 | 一种白蛋白负载金属卟啉配合物纳米颗粒的制备方法及其应用 |
CN108030921B (zh) * | 2017-12-20 | 2021-05-25 | 深圳先进技术研究院 | 一种白蛋白负载金属卟啉配合物纳米颗粒的制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
HK1121373A1 (en) | 2009-04-24 |
CN101156848B (zh) | 2011-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101156848B (zh) | 卟啉类在制备声动力疗法药物中的应用 | |
Kochneva et al. | Photosensitizer Radachlorin®: Skin cancer PDT phase II clinical trials | |
Harth et al. | Modified Topical Photodynamic Therapy of Superficial Skin Tumors, Utilizing Aminolevulinic Acid, Penetration Enhancers, Red Light, and Hypertherntia | |
CN100427062C (zh) | 一种主治急慢性扭挫伤,风湿、类风湿疾病的藏药药物及其制备方法 | |
CN101626773B (zh) | 一种生体治愈促进剂 | |
CN113461697A (zh) | 一种二氢卟吩类化合物及其制备方法和用途 | |
CN105534739A (zh) | 一种复合凝胶 | |
WO2022166993A1 (zh) | 一种新型硼携带剂、制备方法及其药物制剂 | |
Liu et al. | Efficacy of multiple low-dose photodynamic TMPYP4 therapy on cervical cancer tumour growth in nude mice | |
US20210353580A1 (en) | Application of chlorogenic acid and compositions thereof in preparation of drugs for treating squamous cell carcinoma | |
Ivanov et al. | One more PDT application of chlorin e6 | |
CN105560331A (zh) | 一种用于抗皮炎湿疹的药物及其制备方法和应用 | |
CN103417966B (zh) | 一种盐酸氨基乙酰丙酸搽剂及其制备工艺 | |
CN110664807A (zh) | 一种具有协同抗黑色素瘤功效的药物组合物及其应用 | |
CN102266285A (zh) | 一种低刺激性的布洛芬注射液 | |
US8318794B2 (en) | Method of use of porphyrins in preparing a medicament for sonodynamic therapy and a method of sonodynamic therapy using porphyrins | |
CN102988422A (zh) | 美洲大蠊纳米提取物及其制备方法 | |
CN101461850B (zh) | 一种中药组合物在制备治疗痤疮药物中的应用 | |
CN103006622B (zh) | 冰片的新用途及一种治疗肺癌的药物组合物 | |
CN1840116A (zh) | 治疗由人类乳头瘤病毒引起的皮肤和粘膜疾病的外用中药 | |
Pannu et al. | The green blood” wheatgrass juice, a health tonic having antibacterial potential | |
CN109172824A (zh) | 一种用于治疗皮肤鳞状细胞癌的药物组合物及其制备方法 | |
CN104337844A (zh) | 蟾酥提取物及其制剂在制备治疗黑色素瘤药物中的应用 | |
CN103816116B (zh) | 一种治疗皮肤癌的药物及其制备方法 | |
CN105363031B (zh) | α-(8-喹啉氧基)单取代酞菁锌治疗银屑病的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1121373 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU YISI BIOLOGY ENGINEERING SCIENCE AND TEC Free format text: FORMER OWNER: YU BO Effective date: 20091106 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20091106 Address after: Room 2902, Hua Hua building, No. 80, martyrs East Road, Guangzhou, Guangdong, Yuexiu District: 510070 Applicant after: Guangzhou Yisi Bioengineering Technology Co., Ltd. Address before: Shanghai District of Pudong city in 299 Lane Road No. 6 Building 402 room 201204 post encoding: Applicant before: Yu Bo |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1121373 Country of ref document: HK |